New award for bumetanide tablets with exelan pharmaceuticals, INC. Period of performance is may 30, 2026, to may 29, 2027, with four one-year options.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79726D0017
- Awardee
-
Exelan Pharmaceuticals Inc. UEI FYZXNHSQTMG8
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Bumetanide Tablets (VA-26-00011200) Pre-Solicitation · 36E79725R0068 · Posted Oct 16, 2025
- Last date to order 46% complete
- IDV ceiling
- $5,595,064.40
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract to Exelan Pharmaceuticals Inc. for Bumetanide Tablets with a ceiling value of $5,595,064.40 on May 30, 2026.
The contract carries no set-aside designation and was procured through unrestricted competition under RFP 36E79725R0068 issued in commercial item format. The solicitation required offerors to provide exact drug names matching the product label, possess a unique NDC number, and commit to uninterrupted supply throughout the contract period. The procurement serves multiple federal agencies including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers through the VA and DoD Pharmaceutical Prime Vendor Programs.
Estimated annual requirements span five Bumetanide tablet strengths (0.5 mg, 1 mg, and 2 mg) in both 100 and 500 tablet package sizes, with annual usage estimates ranging from approximately 11,493 to 31,067 bottles depending on strength and package configuration.
Performance occurs at Exelan's primary manufacturing and distribution facility in Boca Raton, Florida, with secondary locations in Cary, North Carolina; Summit, New Jersey; and Ottawa, Ontario, Canada, plus designated federal delivery locations as specified by contracting agencies.
The period of performance runs from May 30, 2026, to May 29, 2027, with four one-year option periods. The contract is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and PSC code 6505 (Drugs and Biologicals).
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Add Subcontract Plan | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79726D0017?
36E79726D0017 was awarded to Exelan Pharmaceuticals Inc. by National Acquisition Center (Headquarters) on May 30, 2026.
How much is contract 36E79726D0017 worth?
36E79726D0017's own ceiling is $5,595,064.
Who can order from contract 36E79726D0017?
36E79726D0017 is a single award indefinite delivery contract.
Was contract 36E79726D0017 competed?
The extent of competition for 36E79726D0017 was full and open competition. The government received 6 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV